Gilead Sciences (GILD) News Today → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free Gild Stock Alerts $66.90 -1.00 (-1.47%) (As of 01:15 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 21 at 7:02 AM | marketbeat.comBrown Advisory Inc. Sells 20,825 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Brown Advisory Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 223,552 shares of the biopharmaceutical company's stock afMay 20 at 11:56 PM | marketbeat.com21,827 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Simplicity Wealth LLCSimplicity Wealth LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 21,827 shares of the biopharmaceutical company's stock, valued at approximately $1,599,000. SMay 20 at 2:06 PM | markets.businessinsider.comSeladelpar’s Efficacy in PBC and Strategic Acquisition by Gilead Prompt Buy RatingMay 20 at 2:06 PM | finance.yahoo.comGilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated ItchMay 19 at 9:23 PM | marketbeat.comING Groep NV Raises Stake in Gilead Sciences, Inc. (NASDAQ:GILD)ING Groep NV increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 96.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 931,968 shares of the biopharmaceutical company's stock after acquiring anMay 18 at 11:04 AM | markets.businessinsider.comGilead's Seladelpar Shows Major Liver Disease Progression Improvement, Itch Reduction In PBC StudyMay 18 at 9:37 AM | marketbeat.comMeridian Wealth Management LLC Has $3.31 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)Meridian Wealth Management LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 77.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 40,807 shares of the biopharmaceuMay 18 at 8:30 AM | businesswire.comInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary CholangitisMay 16, 2024 | marketbeat.comARGA Investment Management LP Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)ARGA Investment Management LP boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 635,058 shares of theMay 16, 2024 | marketbeat.comGilead Sciences Q1 Earnings TranscriptMay 15, 2024 | benzinga.comMarket Whales and Their Recent Bets on GILD OptionsMay 15, 2024 | seekingalpha.comGilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript)May 14, 2024 | seekingalpha.comGilead Sciences, Inc. (GILD) BofA Securities 2024 Health Care Conference (Transcript)May 14, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Position Boosted by Mitsubishi UFJ Asset Management Co. Ltd.Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,316,128 shares oMay 14, 2024 | businesswire.comKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell TherapyMay 13, 2024 | marketbeat.comPrincipal Financial Group Inc. Cuts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Principal Financial Group Inc. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,459,552 shares of theMay 13, 2024 | finance.yahoo.comOne stock is dragging down the S&P 500's earnings growthMay 13, 2024 | americanbankingnews.comZacks Research Equities Analysts Reduce Earnings Estimates for Gilead Sciences, Inc. (NASDAQ:GILD)May 12, 2024 | marketbeat.comQRG Capital Management Inc. Has $32.56 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)QRG Capital Management Inc. raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 401,972 shares of the biopharmaceuticMay 11, 2024 | marketbeat.comDimensional Fund Advisors LP Grows Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Dimensional Fund Advisors LP raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,783,195 shares of the biopharmaceutical compMay 10, 2024 | benzinga.comDecoding Gilead Sciences's Options Activity: What's the Big Picture?May 10, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Private Advisor Group LLCPrivate Advisor Group LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 39.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 54,510 shares of the biopharmacMay 9, 2024 | businesswire.comArcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramMay 9, 2024 | businesswire.comKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramMay 9, 2024 | marketbeat.comNational Pension Service Acquires 52,214 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)National Pension Service grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,358,832 shares of the biopharmaceutical company's stock after buying anMay 9, 2024 | forbes.comWill Gilead Sciences Stock Recover To Its Pre-Inflation Shock Highs Of Around $75?May 7, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Boosts Position in Gilead Sciences, Inc. (NASDAQ:GILD)Charles Schwab Investment Management Inc. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,281,489 shares of the biopharMay 7, 2024 | finance.yahoo.comGilead Helps Put African Nation on Path To Eliminate Hepatitis CMay 7, 2024 | businesswire.comGilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024May 6, 2024 | investorplace.comBargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce BackMay 6, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Natixis Advisors L.P.Natixis Advisors L.P. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 15.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 279,620 shares of the biopharmaceutical company's stoMay 5, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lifted by Sheets Smith Wealth ManagementSheets Smith Wealth Management increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 85.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 42,701 shares of the biopharmaceutical company's stock after purchasing an additional 19,64May 4, 2024 | marketbeat.comTodd Asset Management LLC Has $974,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Todd Asset Management LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 95.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,023 shares of the bioMay 3, 2024 | marketbeat.comAmalgamated Bank Sells 19,072 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Amalgamated Bank reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 300,795 shares of the biopharmaceutical company'sMay 3, 2024 | finance.yahoo.comForbes Has Listed Gilead as One of America’s Best Employers for DiversityMay 3, 2024 | marketbeat.comGilead Sciences (NASDAQ:GILD) Sets New 1-Year Low at $64.42Gilead Sciences (NASDAQ:GILD) Sets New 1-Year Low at $64.42May 3, 2024 | marketbeat.comMcAdam LLC Has $1.63 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)McAdam LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 132.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,258 shares of the biopharmaceutical company's stMay 1, 2024 | investorplace.comShhh! 3 Secret Biotech Stocks Flying Below Wall Street's RadarMay 1, 2024 | marketbeat.comGilead Sciences (NASDAQ:GILD) Price Target Lowered to $85.00 at Maxim GroupMaxim Group lowered their target price on Gilead Sciences from $90.00 to $85.00 and set a "buy" rating on the stock in a research note on Wednesday.April 30, 2024 | marketbeat.comNorden Group LLC Raises Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Norden Group LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 240.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,163 shares of the biopharmaceutical company's sApril 30, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)April 30, 2024 | markets.businessinsider.comGilead Sciences: Hold Rating Justified Amid Stable Outlook and Upcoming Oncology CatalystsApril 29, 2024 | marketbeat.comRaymond James & Associates Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Raymond James & Associates cut its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 18.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,031,209 shares of the biopharmaceutical company's stApril 29, 2024 | fool.comGilead Sciences: First-Quarter Results Beat EstimatesApril 29, 2024 | markets.businessinsider.comGilead Sciences: Hold Rating with Cautious Outlook Amidst Market Challenges and Growth UncertaintiesApril 29, 2024 | marketbeat.comTraders Purchase Large Volume of Gilead Sciences Call Options (NASDAQ:GILD)Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) saw unusually large options trading on Monday. Traders bought 28,056 call options on the company. This is an increase of 104% compared to the typical daily volume of 13,758 call options.April 29, 2024 | marketbeat.comBarclays Cuts Gilead Sciences (NASDAQ:GILD) Price Target to $76.00Barclays dropped their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an "equal weight" rating on the stock in a report on Monday.April 29, 2024 | seekingalpha.comGilead Sciences, Inc. (GILD) Q1 2024 Earnings Call TranscriptApril 29, 2024 | marketbeat.comPFG Investments LLC Purchases 27,709 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)PFG Investments LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 298.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 36,988 shares of the biopharmaceutical company's stockApril 27, 2024 | marketbeat.comSector Gamma AS Has $30.98 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Sector Gamma AS reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 38.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 382,362 shares of the biopharmaceutical company's s Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking $16T Elon Musk Crypto Leak (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. GILD Media Mentions By Week GILD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GILD News Sentiment▼0.590.43▲Average Medical News Sentiment GILD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GILD Articles This Week▼1516▲GILD Articles Average Week Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SGEN News Today BIIB News Today NBIX News Today TECH News Today QGEN News Today RGEN News Today CRSP News Today DNLI News Today AMGN News Today MRNA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GILD) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersNext President (Not Trump. Not Biden.)The Freeport SocietyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss Ratings4 Cryptos BETTER than BitcoinTrue Market InsidersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.